Joseph Jimenez
{{about|the businessman|the golfer|Joe Jimenez|the baseball player|Joe Jiménez}}
{{Infobox person
|name = Joseph Jimenez
|image = Joseph Jimenez at the World Economic Forum.jpg
|caption = Jimenez at the World Economic Forum in 2017
|nationality = American
|alma_mater = Stanford University
University of California, Berkeley{{Cite web |url=http://www.novartisfoundation.org/platform/content/element/4381/bio_jimenez_e_final.pdf |title=Novartis Foundation - Home |access-date=2012-03-11 |archive-date=2015-10-04 |archive-url=https://web.archive.org/web/20151004094148/http://www.novartisfoundation.org/platform/content/element/4381/bio_jimenez_e_final.pdf |url-status=dead }}
|occupation = Former CEO of Novartis
}}
Joseph Jimenez is the former CEO of the Swiss pharmaceutical company Novartis.{{cite news|url=https://www.nytimes.com/2011/10/09/business/joseph-jimenez-of-novartis-on-finding-the-core-of-a-problem.html?pagewanted=all&_r=0|title=Fix the Problem, and Not Just the Symptoms|work=New York Times|date=8 October 2011|accessdate=22 May 2013|last1=Bryant|first1=Adam}}
Education
Jimenez earned a bachelor's degree from Stanford University in 1982, and an MBA from Berkeley's Haas School of Business in 1984.{{cite web|url=http://investing.businessweek.com/research/stocks/people/person.asp?personId=1112040&ticker=NVS|archive-url=https://archive.today/20130307210856/http://investing.businessweek.com/research/stocks/people/person.asp?personId=1112040&ticker=NVS|url-status=dead|archive-date=March 7, 2013|title=Joseph Jimenez MBA|publisher=Businessweek|accessdate=22 May 2013}}
Career
=Early career=
Jimenez began his career at Clorox before joining ConAgra Foods.{{cite web|url=https://people.forbes.com/profile/joseph-jimenez/12367 |archive-url=https://web.archive.org/web/20090402063203/http://people.forbes.com/profile/joseph-jimenez/12367 |url-status=dead |archive-date=April 2, 2009 |title=Joseph Jimenez - Forbes |publisher=People.forbes.com |date=2012-04-18 |accessdate=2012-08-02}}{{Cite web|title=P&G investors wish for CEO Joe Jimenez as outgoing Novartis chief joins board|url=https://www.fiercepharma.com/pharma/p-g-investors-wish-for-ceo-joe-jimenez-as-outgoing-novartis-chief-joins-board|access-date=2021-07-27|website=FiercePharma|date=18 December 2017 |language=en}}{{Cite web|last=Buck|first=Jonathan|title=Novartis CEO Writes a Prescription for the Swiss Drug Giant's Success|url=https://online.barrons.com/article/SB50001424052748703320204579079383494209564.html|access-date=2021-07-27|website=online.barrons.com|language=en-US}} Prior to joining Novartis, he was head of H. J. Heinz Company's North American business from 2002 to 2006. He was also a non-executive director of AstraZeneca from 2002 to 2007, as well as an advisor for the Blackstone Group.
Novartis
Jimenez joined Novartis in 2007 as Division Head of Novartis Pharmaceutical and was named CEO in 2010{{cite web|url=http://www.fiercebiotech.com/special-reports/25-most-influential-people-biopharma-today/joseph-jimenez-25-most-influential-people|title=Joseph Jimenez - The 25 most influential people in biopharma today|date=7 February 2012 |publisher=Fierce Biotech|accessdate=22 May 2013}} by his predecessor and Chairman Daniel Vasella.{{cite web|last=Greil |first=Anita |url=https://blogs.wsj.com/source/2010/01/26/vasellas-impeccable-timing/ |title=Vasella's Impeccable Timing - The Source - WSJ |publisher=Blogs.wsj.com |date=2010-01-26 |accessdate=2012-08-02}}
During his time at Novartis, Jimenez increasingly applied standard business metrics to pharma cash flow, purchasing and competitive bidding, confident that his experience in consumer goods would help to realize improvements in Novartis' operations. His cost-cutting moves, focused mostly on marketing and administration, came steadily, with more than a billion cut in 2010, and even more than that in 2011.{{cite web|url=https://www.fiercebiotech.com/special-report/joseph-jimenez-25-most-influential-people-biopharma-today|title=Joseph Jimenez - The 25 most influential people in biopharma today - FierceBiotech|website=www.fiercebiotech.com|date=7 February 2012 }}
Jimenez joined the board of directors at General Motors on June 9, 2015{{cite web |title=About GM: Joseph Jimenez |url=http://www.gm.com/company/aboutGM/board_of_directors0/joseph_jimenez.html |url-status=dead |archive-url=https://web.archive.org/web/20150906055830/http://www.gm.com/company/aboutGM/board_of_directors0/joseph_jimenez.html |archive-date=2015-09-06 |access-date=2023-11-07}}{{cite web |date=2017-12-18 |title=P&G investors wish for CEO Joe Jimenez as outgoing Novartis chief joins board |url=https://www.fiercepharma.com/pharma/p-g-investors-wish-for-ceo-joe-jimenez-as-outgoing-novartis-chief-joins-board |access-date=2023-11-07 |website=Fierce Pharma}}
Jimenez resigned from Novartis, leaving in February 2018, and was succeeded by Vasant Narasimhan.{{cite web|title=Novartis CEO Jimenez to Quit, Giving Reins to Harvard Doctor|url=https://www.bloomberg.com/news/articles/2017-09-04/novartis-names-narasimhan-ceo-after-jimenez-retires-next-year|website=Bloomberg.com|publisher=Bloomberg Technology|accessdate=5 September 2017|date=4 September 2017}}{{Cite news|last=Roland|first=Denise|date=2017-09-04|title=Novartis CEO to Step Down in January|language=en-US|work=Wall Street Journal|url=https://www.wsj.com/articles/novartis-ceo-to-step-down-in-january-1504510846|access-date=2020-05-07|issn=0099-9660}}
He joined the Board of Directors of San Francisco biotech startup uBiome in September 2018 and stepped down in April 2019 to start the biotech venture fund Aditum Bio.{{cite web |last1=Al Idrus |first1=Amirah |title=Biotech Novartis alums Jimenez, Fishman unveil their next act: Aditum Bio |url=https://www.fiercebiotech.com/biotech/novartis-alums-jimenez-fishman-unveil-their-next-act-aditum-bio |website=Fierce Biotech |date=2 November 2020 |publisher=Questex |access-date=Nov 3, 2020}}
Jimenez also has served on the Board of Directors of Procter & Gamble since 2018, where he is lead independent director.{{cite web |date=2017-12-18 |title=P&G investors wish for CEO Joe Jimenez as outgoing Novartis chief joins board |url=https://www.fiercepharma.com/pharma/p-g-investors-wish-for-ceo-joe-jimenez-as-outgoing-novartis-chief-joins-board |access-date=2023-11-07 |website=Fierce Pharma}} He also serves as Chairman of Century Therapeutics, an iPSC derived allogeneic cell therapy company, and is on the Board of Graphite Bio, a gene therapy company.{{cite web |date=2021-05-05 |title=Century Therapeutics Expands Board of Directors with Key Appointments |url=https://www.biospace.com/article/releases/century-therapeutics-expands-board-of-directors-with-key-appointments/ |access-date=2023-11-07 |website=B10Space}}{{cite web |title=Graphite Bio Inc |url=https://www.bloomberg.com/profile/company/1830598D:US?sref=5GnwNQsL |access-date=2023-11-07 |website=Bloomberg}}
References
{{Reflist}}
External links
- [http://www.huffingtonpost.co.uk/joseph-jimenez/improving-healthcare-in-africa_b_1627741.html Joseph Jimenez on Improving Healthcare in Africa - Huffington Post]
{{DEFAULTSORT:Jimenez, Joseph}}
Category:Year of birth missing (living people)